BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 17, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: WHO declares Ebola outbreak a public health emergency of international concernBreaking News: WHO declares Ebola outbreak a public health emergency of international concern
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Silhouettes
Neurology/Psychiatric

Neumora’s M4 receptor positive allosteric modulator enters clinic for schizophrenia

Nov. 27, 2023
Neumora Therapeutics Inc. has announced IND clearance and initiation of a phase I study of NMRA-266 in healthy adults.
Read More
Coronavirus, lungs
Infection

GHRH-R antagonist attenuates pulmonary dysfunction, heart injury in COVID-19 mice

Nov. 27, 2023
Based on previous studies that have demonstrated the potential of growth hormone-releasing hormone receptor (GHRH-R) antagonists to modulate immune responses to bleomycin lung injury, researchers from the University of Miami and affiliated organizations aimed to evaluate the potential of the GHRH-R antagonist MIA-602 in a mouse model of rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury.
Read More
Gastrointestinal

ZHX2 promotes liver recovery after acute liver injury

Nov. 27, 2023
Dysfunction in the mitochondria contributes to the development of acute liver injury (ALI). There is emerging evidence indicating the mitochondria is key to maintain liver homeostasis and survival; thus, controlling its functioning is important for the treatment of liver diseases. Recent findings have identified transcription factor zinc-finger and homeoboxes 2 (ZHX2) to be a critical modulator of liver postnatal gene expression, cell proliferation and lipid homeostasis in the liver.
Read More
Microglia clustering around β-amyloid
Neurology/Psychiatric

Unbiased screen uncovers γ-secretase targets far beyond amyloid

Nov. 27, 2023
By Anette Breindl
Using microglia and an unbiased screening method, investigators have identified almost 60 previously unknown targets for γ-secretase. Investigators from KU Leuven and colleagues published their results in Molecular Cell on Nov. 16, 2023.
Read More
Cancer

Voronoi discovers new EGFR triple-mutant inhibitors for cancer

Nov. 24, 2023
Voronoi Inc. has described EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Suzhou Puhe Biopharma presents new PRMT5 inhibitors

Nov. 24, 2023
Suzhou Puhe Biopharma Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Ningbo Newbay Medical Technology describes new PARP-1 inhibitors for cancer

Nov. 24, 2023
Ningbo Newbay Medical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Eli Lilly divulges new FGFR2 inhibitors for cancer

Nov. 24, 2023
Eli Lilly & Co. has synthesized fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Medshine Discovery patents new SOS1/GTPase KRAS interaction inhibitors

Nov. 24, 2023
Medshine Discovery Inc. has disclosed fused quinazoline compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of solid tumors.
Read More
Heart scientific overlay
Cardiovascular

4-Hydroxynonenal inhibition of Dicer directly impairs miRNA biogenesis in heart failure

Nov. 24, 2023
4-Hydroxynonenal (4-HNE) is a major byproduct of lipid peroxidation, a process exacerbated by mitochondrial dysfunction and oxidative stress. Accumulation of 4-HNE protein adducts has been reported in several cardiovascular diseases, such as myocardial infarction, hypertension and heart failure in both rodents and humans. Therefore, identifying critical 4-HNE targets relevant to cardiac pathophysiology could help develop better therapies to treat heart failure.
Read More
Previous 1 2 … 890 891 892 893 894 895 896 897 898 … 18070 18071 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • Illustration of tau accumulating in a neuron cell.

    Biogen AD drug shows tau, cognition benefit, despite trial miss

    BioWorld
    Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing